arrow
J

James S. Blachly

The Ohio State University
H指数:39
被引数:6,096

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Epigenetic markers expand genetic risk estimation in acute myeloid leukemia

表观遗传标记扩展急性髓系白血病的遗传风险评估

Blood
IF23.1
2026-09-110
OA
Updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia (HCL) and HCL variant

毛细胞白血病(HCL)和HCL变异型的诊断与管理更新共识指南

Blood
IF23.1
2026-04-160
PRE
Reversible cerebral vasoconstriction syndrome following ciltacabtagene autoleucel therapy for relapsed multiple myeloma: a case report

ciltacabtagene autoleucel疗法治疗复发多发性骨髓瘤后出现的可逆性脑动脉收缩综合征:一份病例报告

2026-04-030
OAAI
Real-world experience of venetoclax target dosing with concomitant posaconazole in adult patients with acute myeloid leukemia

成人急性髓系白血病患者接受维奈克拉 target dosing 并联泊沙康唑的实况经验

2025-09-230
OAAI
Multi-dimensional analysis of adult acute myeloid leukemia cross-continents reveals age-associated trends in mutational landscape and treatment outcomes (Acute Myeloid Leukemia Cooperative Group & Alliance for Clinical Trials in Oncology)

跨大陆成人急性髓系白血病的多维分析揭示了突变景观和治疗结局中的年龄相关趋势(Acute Myeloid Leukemia Cooperative Group & Alliance for Clinical Trials in Oncology)

Leukemia
IF13.4
2025-09-190
OAAI
qcCHIP: an R package to identify clonal hematopoiesis variants using cohort-specific data characteristics

qcCHIP: 一个用于利用队列特异性数据特征识别克隆性造血变异的R软件包

2025-09-010
PRE
Real-World Experience of Venetoclax Target Dosing with Concomitant Posaconazole in Adult Patients with Acute Myeloid Leukemia

急性髓系白血病成人患者中,与泊沙康唑联合使用的维奈克拉靶向剂量给药的实战经验

BLOOD
IF23.1
2024-11-050
PRE
A Phase I Study to Evaluate the Safety and Tolerability of Gemtuzumab Ozogamicin and Midostaurin When Used in Combination with Standard Cytarabine and Daunorubicin Induction for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia

一项I期研究,旨在评估吉姆单抗奥佐米星和米哚妥林在联合标准剂量阿糖胞苷和柔红霉素诱导治疗新诊断FLT3突变急性髓性白血病时的安全性与耐受性。

BLOOD
IF23.1
2024-11-050
PRE
Comparison of Two Myeloablative Total-Body Irradiation (MAC-TBI) Regimens: 1200 Cgy Vs 800 Cgy of TBI for Allogeneic Stem Cell Transplantation in Adults with Hematological Malignancies

比较两种骨髓清除性全身照射(MAC-TBI)方案:用于成人血液系统恶性肿瘤异基因干细胞移植的1200 Cgy与800 Cgy TBI剂量比较

BLOOD
IF23.1
2024-11-050
PRE
GATA2-Mutated AML: Clinical Outcomes and Spectrum of Infections in Patients Undergoing or Not Allogeneic Stem Cell Transplantation

GATA2突变AML:接受或不接受异基因干细胞移植患者的临床结局及感染谱

BLOOD
IF23.1
2024-11-050
PRE
Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia

多组学分析确定非裔美国急性髓系白血病患者的生存预测因子

2024-10-041
OAAI
White blood cell count levels are associated with inflammatory response and constitute independent outcome predictors in adult patients with acute myeloid leukemia aged <60 years
2024-09-160
PRE
Hairy cell leukemia variant and WHO classification correspondence Re: 5th edition WHO classification haematolymphoid tumors: lymphoid neoplasms
LEUKEMIA
IF13.4
2024-06-084
OAAI
The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signaling

多CDK抑制剂dinaciclib通过抑制Wnt/β-catenin信号转导逆转急性髓细胞白血病的溴和末端外结构域 (BET) 抑制剂耐药性

2024-03-042
OAAI
Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG)
LEUKEMIA
IF13.4
2023-11-289
OAAI
Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study
2023-08-142
OAAI
Association of social deprivation with survival in younger adult patients with AML: an Alliance study
2023-07-284
OAAI